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Objective: To assess benefits and harms of cognitive-behavioral therapy (CBT) versus no intervention or versus other interventions for pediatric
obsessive-compulsive disorder (OCD).
Method: We searched for randomized clinical trials of CBT for pediatric OCD. Primary outcomes were OCD severity, serious adverse events, and
level of functioning. Secondary outcomes were quality of life and adverse events. Remission from OCD was included as an exploratory outcome. We
assessed risk of bias and evaluated the certainty of the evidence with the Grading of Recommendations Assessment, Development and Evaluation
(GRADE).
Results: Nine trials (N ¼ 645) were included comparing CBT with no intervention and 3 trials (N ¼ 146) comparing CBT with selective serotonin
reuptake inhibitors (SSRIs). Compared with no intervention, CBT decreased OCD severity (mean difference [MD] ¼ 8.51, 95% CI ¼ 10.84
to 6.18, p < .00001, low certainty), improved level of functioning (patient-rated: standardized MD [SMD] ¼ 0.90, 95% CI ¼ 1.19 to 0.62,
p < .00001, very low certainty; parent-rated: SMD ¼ 0.68, 95% CI ¼ 1.12 to 0.23, p ¼ .003, very low certainty), had similar proportions of
participants with adverse events (risk ratio ¼ 1.06, 95% CI ¼ 0.931.22, p ¼ .39, GRADE: low certainty), and was associated with reduced risk of still
having OCD (risk ratio ¼ 0.50, 95% CI ¼ 0.370.67, p < .00001, very low certainty). We had insufficient data to assess the effect of CBT versus no
intervention on serious adverse events and quality of life. Compared with SSRIs, CBT led to similar decreases in OCD severity (MD ¼ 0.75, 95%
CI ¼ 3.79 to 2.29, p ¼ .63, GRADE: very low certainty), and was associated with similar risk of still having OCD (risk ratio ¼ 0.85, 95% CI ¼
0.661.09, p ¼ .20, very low certainty). We had insufficient data to assess the effect of CBT versus SSRIs on serious adverse events, level of functioning,
quality of life, and adverse events.
Conclusion: CBT may be more effective than no intervention and comparable to SSRIs for pediatric OCD, but we are very uncertain about the effect
estimates.
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64bsessive-compulsive disorder (OCD) is among
the most common psychiatric disorders, with an
estimated prevalence of 1% to 3% in childrenand adolescents.1,2 Pediatric OCD is associated with
reduced quality of life, as well as familial, social, and
occupational impairment.3-7
The recommended first-line treatment for pediatric
OCD is cognitive-behavioral therapy (CBT) including
exposure and response prevention.5,8 Previous reviews
support the recommendation of CBT for pediatric OCD,9-18
but limitations such as not assessing risk of bias in includedwww.jaacap.orgtrials,9-13 pooling results from randomized trials and
noncontrolled studies,9,13,14 or including only symptom
severity as an outcome measure15-17 may have led to
inaccurate conclusions regarding the efficacy of CBT.
In this systematic review, we assessed beneficial and
harmful effects of CBT versus no intervention and versus
other interventions, in terms of symptom severity, level of
functioning, quality of life, lack of remission, and adverse
events, for OCD in children and adolescents. We assessed
risk of bias in included trials, controlled for random errors
due to sparse data or multiple testing using trial sequentialJournal of the American Academy of Child & Adolescent Psychiatry
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CBT FOR PEDIATRIC OCDanalysis (TSA),19 and evaluated the certainty of the evidence
using the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach.20
METHOD
Protocol and Registration
The protocol for this systematic review was registered with
PROSPERO on November 28, 2017 (CRD42017079118).
Search Strategy
We systematically searched for eligible trials in Cochrane’s
CENTRAL, MEDLINE, PsycINFO, EMBASE, LILACS,
Science Citation Index Expanded on Web of Science, SSCI,
and BIOSIS. The search strategy for MEDLINE is provided
in Supplement 1, available online. Details on the search are
provided in the protocol.
Trial Selection
Three authors (CU, VU, and LP) independently screened
titles and abstracts and retrieved and screened all relevant
full-text articles for eligibility. A fourth author (NL) was
consulted to solve any discrepancies. We included all ran-
domized clinical trials of CBT for children and adolescents
(as defined by trialists) with a primary diagnosis of OCD,
according to a standard diagnostic system (ie, the Interna-
tional Classification of Diseases [ICD]21 or the Diagnostic and
Statistical Manual of Mental Disorders [DSM]22). We
included trials irrespective of language, setting, publica-
tion status, and publication year. We accepted any type
of CBT defined as CBT by trialists. We accepted any
non-CBT control intervention. Trials comparing CBT
plus a co-intervention with the co-intervention alone
(eg, CBT þ selective serotonin reuptake inhibitors
[SSRIs] versus SSRI) were included if the co-intervention
was delivered similarly in the experimental and control
groups.
Data Extraction and Outcomes
Three reviewers (CU, VU, and LP) independently extracted
the following information from full-text articles of each
included trial: author names; publication year; trial location;
participant characteristics; sample size; interventions
(number of sessions/dosage, duration, and format); mean
scores and SDs for each specified outcome at baseline, end
of treatment, and maximum follow-up; and information for
risk of bias assessment. Our primary outcomes were: (1)
symptom severity assessed with the Children’s YaleLBrown
Obsessive-Compulsive Scale (CY-BOCS)23; (2) serious
adverse events, defined as death, any life-threatening event,
hospitalization, persistent or significant loss of function, or
disability24; and (3) level of functioning measured on anyJournal of the American Academy of Child & Adolescent Psychiatry
Volume 59 / Number 1 / January 2020validated scale. Our secondary outcomes were: (1) quality of
life measured on any validated scale; and (2) adverse events,
defined as any adverse event not classified as a serious
adverse event. Our exploratory outcome was lack of
remission from OCD diagnosis.
Risk of Bias Evaluation
We used the guidelines provided in the Cochrane Handbook
for Systematic Reviews of Interventions to evaluate risk of bias
in the included trials.25 Three authors (CU, VU, and LP)
independently classified the trials according to specific
criteria (detailed in the protocol). Disagreements were
resolved with a third author (JJ). We assessed selection bias
(allocation sequence generation and allocation conceal-
ment), performance bias (blinding of trial participants and
treatment providers), detection bias (blinding of outcome
assessors), attrition bias (incomplete outcome data),
reporting bias (selective outcome reporting), and other bias
(eg, vested interest bias). Only trials assessed at low risk of
bias within all assessed domains were classified as trials at
overall low risk of bias.
Data Synthesis and Meta-analyses
We followed the recommendations of the Cochrane Hand-
book for Systematic Reviews of Interventions,25 Keus et al.,26
and the eight-step assessment for meta-analyses described
by Jakobsen et al.27 We used Cochrane’s Review Manager
528 to analyze data.
For continuous outcomes, we calculated mean differ-
ences (MDs) with 95% CIs. When different scales were
used to measure the same outcome type, we calculated
standardized mean differences (SMDs) by dividing the MD
between a CBT and control group by the pooled SD at end
of treatment. To aid interpretation of the intervention ef-
fect, we re-expressed SMDs in the unit of the scale most
commonly used in the included trials by multiplying the
SMD with the pooled SD at end of treatment of the CBT
and control groups that had scores on this scale.29 We
multiplied scores by L1 for scales on which increases
represent beneficial outcomes, to ensure consistent direc-
tionality across scales. For dichotomous outcomes, we
calculated risk ratios with 95% CIs. For all outcomes, the
intervention effects were assessed with both random-ef-
fects30 and fixed-effect31 meta-analyses, and the most con-
servative estimate was reported as the main result.27 If the
two estimates were similar, we used the estimate with the
widest CI. We planned to assess three primary and two
secondary outcomes. Following the recommendations of
Jakobsen et al., we therefore considered a p value of .025
for primary outcomes and of .033 for secondary outcomes
as thresholds for statistical significance.27 We used thewww.jaacap.org 65
UHRE et al.conventional p value of .05 for the exploratory outcome.
We inspected forest plots and trial characteristics to identify
potential sources of heterogeneity. We assessed the presence
and quantities of statistical heterogeneity by the I2 statistic,
with significance set at p < .10.32,33 When multiple inter-
vention groups were reported in a single trial, we included
only the relevant groups. If two comparisons from the same
trial were combined in the same meta-analysis, we halved
the control group to avoid double counting.25
We contacted trial authors to obtain missing data for
quantitative analyses and risk of bias assessment. For
continuous outcomes, we calculated SDs using other re-
ported data when necessary (eg, calculating SDs from re-
ported CIs or standard errors).
Trial Sequential Analysis
Meta-analyses run the risk of random errors due to sparse
data and repetitive testing of accumulating data when
updating reviews.19,34 We controlled for risks of false-
positive results (type I errors) and false-negative results
(type II errors), and estimated the information size required
to detect or reject an anticipated minimal clinically relevant
difference between comparison groups by performing
TSA19 on each outcome (details are provided in the pro-
tocol and the TSA manual35).
Planned Subgroup Analyses
We performed the following planned subgroup analyses for
the primary outcomes (CY-BOCS score, serious adverse
events, and level of functioning) when at least two trials or
comparisons provided data for the analysis: type of control
intervention, type of CBT assessed (ie, individual, group
format, or Internet-based), and trials with blinded outcome
assessors compared to trials without blinded outcome as-
sessors. We had insufficient data for the following planned
subgroup analyses for all primary outcomes: trials at low risk
of bias versus trials at high risk of bias, children (<13 years
of age) versus adolescents (13 years of age), severe OCD
versus mild to moderate OCD, and OCD with one or more
comorbid psychiatric disorders versus OCD without co-
morbidity. We used the test for subgroup differences in
Review Manager.28
Sensitivity Analyses
We performed sensitivity analyses to assess the potential
impact of missing data. A “best/worst” scenario was assessed
for continuous outcomes by assuming that all patients lost
to follow-up in CBT had a beneficial outcome (the group
mean plus 2 SD) and that all patients lost to follow-up in
the control group had a harmful outcome (the group mean
minus 2 SD). A “best/worst” scenario was assessed for66 www.jaacap.orgdichotomous outcomes by assuming that no patients lost to
follow-up in CBT had an event and that patients lost to
follow-up in the control group had an event. In addition, we
assessed the reverse “worst/best” scenarios for all outcomes.
As supplementary analyses, we repeated all analyses for
continuous outcomes with 1 SD instead of 2 SD.27
Protocol Deviations
In our protocol, we defined remission as not meeting the
criteria for OCD as assessed with a diagnostic interview or
having a CY-BOCS score 12 in combination with a
Clinical Global Impression–Severity (CGI-S) score of 1 (not
at all ill) or 2 (borderline mentally ill).36 However, as only
three trials assessed remission in either of these ways, we
accepted any reported measure of remission.
RESULTS
Study Selection and Characteristics
We completed the primary search on July 27, 2017, and the
latest search on November 21, 2018 (see the PRISMA flow
diagram37 in Figure S1, available online). Study character-
istics are presented in Table S1, available online. Twelve
randomized clinical trials were eligible for inclusion in the
review (nanalyzed ¼ 819; age range 418 years; 52% female
patients; 65% patients with 1 comorbid disorder; baseline
mean CY-BOCS score ¼ 23.9; 514 planned CBT ses-
sions delivered over 1214 weeks). Five trials38-42
compared CBT with waitlist. Three trials43-45 compared
CBT with a control intervention including psychoeducation
and relaxation training, defined as placebo psychotherapy in
all three trials. Two trials46,47 compared CBT with “no
intervention” with SSRI co-intervention delivered similarly
in both groups (ie, CBTþSSRI versus SSRI); one of these
trials47 also included an active control comparison of CBT
versus pill-placebo. In total, three eligible trials47-49
compared CBT with SSRI. Based on the trials identified,
we did two comparisons: (1) CBT versus “no intervention”
(including waitlist, placebo, and no intervention, with a co-
intervention delivered similarly in the experimental and
control groups); and (2) CBT versus SSRIs. We calculated
effects of interventions only at end of treatment, as we had
insufficient data to evaluate long-term effects. We found no
substantial discrepancies between effect estimates from
random-effects and fixed-effect meta-analyses (see Table S2,
available online).
Risk of Bias Assessment
Details on the assessment of risk of bias are presented in
Figure 1. All trials and all meta-analysis results were rated at
overall high risk of bias. Given the nature of psychothera-
peutic interventions, no trial had adequate blinding ofJournal of the American Academy of Child & Adolescent Psychiatry
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FIGURE 1 Risk of Bias in the Included Randomized Clinical
Trials
Note: Random allocation sequence generation was adequate in 10 of 12 trials
(83%); allocation concealment was adequate in 5 of 12 trials (42%); blinding of trial
participants and treatment providers was adequate in 0 of 12 trials (0%); blinding of
outcome assessors was adequate in 9 of 12 trials (75%); there was low risk of bias
for “incomplete outcome data” in 4 of 12 trials (33%); there was low risk of bias for
“selective outcome reporting” in 12 of 12 trials (100%); and the “other bias”
domain (eg, vested interest) was adequate in 10 of 12 trials (83%). Green (þ) ¼
low risk of bias; yellow (?) ¼ unclear risk of bias; red () ¼ high risk of bias. Please
note color figures are available online.
CBT FOR PEDIATRIC OCDparticipants and treatment providers. Only one trial40 had
low risk of bias in the remaining bias domains and was
therefore potentially less affected by bias.
Comparison 1: CBT Versus “No Intervention”
Primary Outcome: Children’s YaleBrown Obsessive-
Compulsive Scale. Ten trials38-47 (nanalyzed ¼ 701; 13
comparisons) tested the efficacy of CBT in reducing OCD
symptom severity on the CY-BOCS scale versus a controlJournal of the American Academy of Child & Adolescent Psychiatry
Volume 59 / Number 1 / January 2020condition considered ineffective for OCD. Five trials38-42
used waitlist control; two trials46,47 used “no intervention”
with an SSRI co-intervention applied equally in both
comparison groups (one of these trials47 also included a
control condition with pill-placebo); and three trials43-45
used placebo psychotherapy. Random-effects meta-analysis
showed evidence of a difference in favor of CBT versus “no
intervention” (MD ¼ 8.51, 95% CI ¼ 10.84 to 6.18,
p < .00001) (Figure 2). TSA showed that this finding is
unlikely to be a random finding due to lack of power or
multiple testing (Figure S2, available online). Missing
outcome analysis showed that the finding is unlikely to have
been caused by missing outcome data bias (Table S3,
available online).
The I2 was 79% (c2 ¼ 56.93, p < .00001), suggesting
substantial heterogeneity. Visual inspection of the forest
plot indicated heterogeneity primarily in the CBT versus
waitlist comparison. In 238,41 of the 5 trials comparing CBT
with waitlist, the waitlist duration was considerably shorter
than the CBT duration (eg, 12 weeks of CBT versus 4
weeks of waitlist). Excluding these trials from the analysis
reduced I2 to 45% but did not substantially alter the meta-
analysis result (MD ¼ 6.81, 95% CI ¼ 8.45 to 5.18,
p < .00001). Subgroup analyses showed no evidence of
differences between the types of control conditions, but did
show evidence of a difference in favor of conventional CBT
versus Internet-delivered CBT (see Supplement 2, available
online).
Primary Outcome: Serious Adverse Events. Three tri-
als40,44,46 assessed serious adverse events for CBT versus a
control considered ineffective for OCD. One trial40 used
waitlist control, one trial46 used “no intervention” with an
SSRI co-intervention, and one trial44 used placebo psy-
chotherapy. None of the 137 patients in CBT experienced a
serious adverse event compared with one of 138 patients
(0.7%) in the “no intervention” group. The reported event
was a suicide attempt by a participant with comorbid
depression in a “no intervention” with SSRI in the co-
intervention group. We did not perform meta-analysis,
missing outcome analysis, or TSA for serious adverse
events, because no events were observed for CBT and only
one event was observed for “no intervention.”
Primary Outcome: Level of Functioning. Five trials39-41,44,45
(nanalyzed ¼ 377, 6 comparisons) assessed the effect of
CBT on level of functioning versus a control considered
ineffective for OCD. Three trials39-41 used a waitlist
control, and two trials44,45 used placebo psychotherapy.
Three trials39,41,45 used the Child Obsessive-Compulsive
Impact Scale–child rated (COIS-C) and –parent rated
(COIS-P); one trial40 used the Education, Work andwww.jaacap.org 67
FIGURE 2 Effect of Cognitive-Behavioral Therapy Versus “No Intervention” on Severity of Obsessive-Compulsive Disorder
Measured on the Children’s YaleBrown Obsessive-Compulsive Scale
Note: CBT ¼ cognitive behavioral therapy; SSRI ¼ selective serotonin reuptake inhibitors. Please note color figures are available online.
UHRE et al.Social Adjustment Scale–child rated (EWSAS-C) and
–parent rated (EWSAS-P); and one trial44 used only
COIS-P.
Patient-Rated Level of Functioning. Fixed-effect meta-
analysis on patient-rated level of functioning showed
evidence of a difference in favor of CBT versus “no inter-
vention” (SMD ¼ –0.90, 95% CI ¼ –1.19 to –0.62, p <
.00001) (Figure 3a). Missing outcome analysis showed that
this finding is unlikely to have been caused by missing
outcome data bias (Table S3, available online). Restricting
the analysis to the three trials reporting results from COIS-
C did not substantially alter the meta-analysis result. TSA
restricted to the trials reporting results from COIS-C
showed that this finding is unlikely to be a random
finding due to lack of power or multiple testing (Figure S3,
available online).
The I2 was 83% (c2 ¼ 23.86, p < .0001), suggesting
substantial heterogeneity. Visual inspection of the forest
plot indicated that one trial39 had a markedly larger inter-
vention effect estimate. Excluding this trial from the analysis
reduced I2 to 40% but did not substantially alter the68 www.jaacap.orgmeta-analysis result. Subgroup analyses showed no evidence
of differences between the types of control conditions, but
did show evidence of a difference in favor of conventional
CBT versus Internet-delivered CBT (Supplement 2, avail-
able online).
Parent-Rated Level of Functioning. Random-effects meta-
analysis on parent-rated level of functioning showed
evidence of a difference in favor of CBT versus “no inter-
vention” (SMD ¼ –0.68, 95% CI ¼ –1.12 to –0.23,
p ¼ .003) (Figure 3b). Missing outcome analysis showed
that this finding is sensitive to missing outcome data bias
(Table S3, available online). TSA restricted to the trials
reporting results from COIS-P showed that this finding may
be a random finding due to lack of power or multiple
testing (Figure S4, available online).
The I2 was 73% (c2 ¼ 18.64, p ¼ .002), suggesting
substantial heterogeneity. Visual inspection of the forest
plot indicated that one trial39 had a markedly larger inter-
vention effect estimate. Excluding this trial from the
analysis reduced I2 to 0% but did not substantially alter the
meta-analysis result. Subgroup analyses showed no evidenceJournal of the American Academy of Child & Adolescent Psychiatry
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FIGURE 3 Effect of Cognitive-Behavioral Therapy Versus “No Intervention” on Patient-Rated Level of Functioning (a) and
Parent-Rated Level of Functioning (b)
Note: CBT ¼ cognitive-behavioral therapy. Please note color figures are available online.
CBT FOR PEDIATRIC OCDof differences between the types of control conditions
(Supplement 2, available online).
Secondary Outcome: Quality of Life. Two trials39,44
(nanalyzed ¼ 223, 3 comparisons) assessed the effect of
CBT on quality of life versus a control considered inef-
fective for OCD. One trial39 used waitlist control and
assessed quality of life with the Manchester Short Assess-
ment of Quality of Life (MANSA). One trial44 used pla-
cebo psychotherapy and assessed quality of life with theJournal of the American Academy of Child & Adolescent Psychiatry
Volume 59 / Number 1 / January 2020Pediatric Quality of Life Enjoyment and Satisfaction
Questionnaire (PQ-LES-Q). Random-effects meta-analysis
suggested a difference in favor of CBT versus “no inter-
vention” (SMD ¼ –0.39, 95% CI ¼ –0.77 to –0.02, p ¼
.04) (Figure S5, available online), although this effect did
not meet our predefined significance threshold of p 
0.025. Missing outcome analysis showed that this finding is
sensitive to missing outcome data bias (Table S3, available
online). The I2 was 33% (c2 ¼ 2.98, p ¼ .23), suggesting
negligible heterogeneity. We had insufficient data for TSA.www.jaacap.org 69
UHRE et al.Secondary Outcome: Adverse Events. Three trials40,44,46
(nanalyzed ¼ 275, 3 comparisons) assessed adverse events
for CBT versus a control considered ineffective for OCD.
One trial40 used waitlist control, one trial46 used “no
intervention” with an SSRI co-intervention, and one trial44
used placebo psychotherapy. A total of 49 of 137 patients
(35.8%) in CBT experienced an adverse event compared
with 44 of 138 patients (31.9%) in the “no intervention.”
Two of the trials40,44 reported the types of adverse events.
In one trial,40 the events recorded were mood problems
(9%), OCD-related symptoms (6%), anxiety (4%), and
sleep problems (1%). The overall occurrence was similar
between the groups, and no type of event was more com-
mon in either group. The other trial44 recorded a single
event of aggressive impulsive behavior in the CBT group.
Random-effects meta-analysis showed no evidence of a
difference between CBT and “no intervention” in the risk of
experiencing an adverse event (RR ¼ 1.06, 95% CI 0.93–
1.22, p ¼ 0.39) (Figure S6, available online). TSA showed
that this finding may be a random finding due to lack of
power or multiple testing (Figure S7, available online).
Missing outcome analysis showed that the finding is un-
likely to have been caused by missing outcome data bias
(Table S3, available online). The I2 was 0% (c2 ¼ 1.08,
p ¼ .58), suggesting negligible heterogeneity.
Exploratory Outcome: Lack of Remission. Seven trials38-41,43,45,47
(nanalyzed ¼ 480, 10 comparisons) assessed the risk of still
having OCD at end of CBT compared with a control
considered ineffective for OCD. Four trials38-41 used waitlist
control; one trial47 used “no intervention” with an SSRI co-
intervention and included an additional control condition
with pill-placebo; and two trials43,45 used placebo psycho-
therapy. Two trials38,39 used the Anxiety Disorders Interview
Schedule–parent version (ADIS-P) clinical interview to assess
remission; one trial40 used a combination of CY-BOCS
score 12 and CGI-S score 2; one trial41 used a combi-
nation of ADIS-P severity rating 3 and CY-BOCSFIGURE 4 Effect of Cognitive-Behavioral Therapy Versus Selectiv
Compulsive Disorder Measured on the Children’s YaleBrown O
Note: CBT ¼ cognitive behavioral therapy; SSRI ¼ selective serotonin reuptake inhibit
70 www.jaacap.orgscore 10; one trial47 used CY-BOCS score 10, one
trial45 used CY-BOCS score 11; and one trial43 used CY-
BOCS score 12. A total of 141 of 295 patients (47.8%)
in CBT compared with 171 of 185 patients (92.4%) in the
“no intervention” group still had OCD at the end of treat-
ment. Random-effects meta-analysis showed that patients
were less likely to still have OCD at the end of treatment
in the CBT versus “no intervention” group (RR ¼ 0.50,
95% CI ¼ 0.37–0.67, p < .00001) (Figure S8, available
online). TSA showed that this finding is unlikely to be a
random finding due to lack of power or multiple testing
(Figure S9, available online). Missing outcome analysis
showed that the finding is unlikely to have been caused
by missing outcome data bias (Table S3, available
online).
The I2 was 82% (c2 ¼ 50.34, p < .00001), suggesting
substantial heterogeneity. Visual inspection of the forest
plot indicated that one trial40 had a smaller intervention
effect estimate and markedly smaller CI. Excluding this trial
from the analysis reduced I2 to 58% but did not substan-
tially alter the meta-analysis result.
Comparison 2: CBT Versus Pharmacological Intervention
Primary Outcome: Children’s YaleBrown Obsessive-
Compulsive Scale. Three trials47-49 (nanalyzed ¼ 146, 3
comparisons) tested the efficacy of CBT in reducing OCD
symptom severity assessed with CY-BOCS versus an SSRI
intervention. One trial48 did not report end-of-treatment
CY-BOCS scores and SDs. As we were unable to obtain
these data from the trial authors, we used values retrieved by
authors of a previous review.50 Random-effects meta-analysis
showed no evidence of a difference between CBT and SSRI
(MD ¼ –0.75, 95% CI ¼ –3.79 to 2.29, p ¼ .63)
(Figure 4). TSA showed that this finding is unlikely to be a
random finding due to lack of power or multiple testing
(Figure S10, available online). Missing outcome analysis
showed that the finding is unlikely to have been caused by
missing outcome data bias (Table S4, available online). Thee Serotonin Reuptake Inhibitors on Severity of Obsessive-
bsessive-Compulsive Scale
ors. Please note color figures are available online.
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CBT FOR PEDIATRIC OCDI2 was 17% (c2 ¼ 2.40, p ¼ .30), suggesting negligible
heterogeneity.
Primary Outcome: Serious Adverse Events. Three trials47-49
assessed serious adverse events for CBT versus an SSRI
intervention. However, two of these trials47,49 assessed only
SSRI-related serious adverse events. The remaining trial48
reported having assessed serious adverse events in both
comparison groups but did not report numbers of events or
participants affected.
Primary Outcome: Level of Functioning. One trial49
(nanalyzed ¼ 50, one comparison) assessed the effect of CBT
on level of functioning versus an SSRI intervention. This trial
assessed patient-rated level of functioning with COIS-C and
parent-rated level of functioning with COIS-P. There was no
evidence of a difference between CBT and SSRI on parent-
rated level of functioning (MD ¼ 1.70, 95% CI ¼ –6.45
to 9.85, p ¼ .68) or patient-rated level of functioning (MD ¼
6.95, 95% CI ¼ 0.15–13.75, p ¼ .05).
Secondary Outcome: Quality of Life. No trials assessed the
effect of CBT on quality of life versus an SSRI intervention.
Secondary Outcome: Adverse Events. Three trials47-49
assessed adverse events for CBT versus an SSRI interven-
tion. However, two of these trials47,49 assessed only SSRI-
related adverse events. The remaining trial48 assessed
adverse events in both comparison groups. This trial re-
ported more weight loss in the SSRI group and more nausea
and abdominal discomfort in the CBT group, but did not
report numbers of events or participants affected.
Exploratory Outcome: Lack of Remission. Two trials47,49
(nanalyzed ¼ 106, 2 comparisons) assessed the risk of still hav-
ing OCD at end of CBT compared with an SSRI intervention.
Both trials defined remission as CY-BOCS score 10. A total
of 36 of 56 patients (64.3%) in CBT compared with 38 of 50
patients (76.0%) in the SSRI intervention still had OCD at the
end of treatment. Random-effects meta-analysis showed no
evidence of a difference between CBT and SSRI intervention in
the likelihood of still having OCD (RR ¼ 0.85, 95% CI ¼
0.66–1.09, p ¼ .20) (Figure S11, available online). TSA
showed that this findingmay be a random finding due to lack of
power or multiple testing (Figure S12, available online).
Missing outcome analysis showed that the finding is unlikely to
have been caused by missing outcome data bias (Table S4,
available online). The I2 was 0% (c2 ¼ 0.53, p ¼ .47), sug-
gesting negligible heterogeneity.
Publication Bias
We did not have enough trials, and the clinical het-
erogeneity was too substantial, to perform any of theJournal of the American Academy of Child & Adolescent Psychiatry
Volume 59 / Number 1 / January 2020assessments of publication bias specified in our
protocol.
GRADE Assessment
The GRADE assessments are presented in Table 1. The
certainty of evidence was low or very low for all
outcomes.
DISCUSSION
We included 12 randomized clinical trials in the present
systematic review of CBT for pediatric OCD. First, we
compared CBT with “no intervention.” Our primary an-
alyses showed that CBT may substantially reduce OCD
symptom severity and may moderately improve level of
functioning when compared with “no intervention”,
whereas we were unable to assess the effect on serious
adverse events due to sparse data. Our secondary analyses
showed that CBT and “no intervention” may have similar
effects on quality of life, and may lead to similar pro-
portions of participants experiencing adverse events,
although TSA analysis suggested that the latter may be a
random finding due to lack of power or multiple testing.
Our exploratory analysis showed that CBT may have a
substantial beneficial effect on remission when compared
with “no intervention”, although approximately one-half
of patients in CBT were classified as nonremitters at the
end of treatment.
It is possible that the relatively high proportion of
participants affected by adverse events in the CBT and “no
intervention” groups (35.8% and 31.9%, respectively) is
partly related to high rates of concomitant use of SSRI in
the 2 groups (36.2% and 34.3%, respectively). Indeed,
some overlap exists between the adverse events reported
here and known SSRI side effects in children and ado-
lescents,51 and the trial44 reporting the lowest proportions
of participants experiencing adverse events (1 of 63 par-
ticipants in CBT and 0 of 64 participants in the “no
intervention” group) also had the lowest rate of concom-
itant use of SSRI (2%). Nevertheless, as we do not have
data to disentangle CBT-related adverse events and adverse
events related to concomitant use of SSRI, the main
finding is that knowledge about harmful effects of CBT is
lacking.
Next, we compared CBT with SSRI interventions. Our
primary analyses showed that CBT and SSRIs may have
comparable effects on OCD symptom severity, whereas we
were unable to assess the effect on serious adverse events and
level of functioning due to sparse data. Secondary analyses
on quality of life and adverse events were not possible. Our
exploratory analysis showed that CBT and SSRI may have
comparable beneficial effects on remission, although TSAwww.jaacap.org 71
TABLE 1 Summary of Findings Tables for Cognitive-Behavioral Therapy Versus “No Intervention” and Versus Selective
Serotonin Reuptake Inhibitors
CBT vs. “No Intervention” for OCD in Children and Adolescents
Outcomes
Anticipated Absolute Effects
(95% CI)
Relative Effect
(95% CI)
No. of
Participants
(Trials)
Certainty of the
Evidence
(GRADE) Comments
Risk With “No
intervention” Risk With CBT
Severity of OCD Mean severity of
OCD was 8.51
lower in CBT
(10.84 lower to
6.18 lower)
— 701 (10) 44
LOW a,b
CBT may result in a
large reduction in
severity of OCD.
Serious adverse
events
7 per 1,000 2 per 1,000
(0L58)
RR 0.33
(0.01L 7.96)
275 (3) 4
Very low a,c,d
We are very
uncertain about
the effect of CBT
on serious
adverse events.
Level of
functioning
(patient-rated)
— SMD 0.90 lower
(1.19 lower to
0.62 lower)
— 250 (4) 4
Very low a,b,c,e
CBT may improve
level of
functioning
(patient-rated)
but we are very
uncertain. Note:
lower scores
represent higher
level of
functioning.
Level of
functioning
(parent-rated)
— SMD 0.68 lower
(1.12 lower to
0.23 lower)
— 377 (5) 4
Very low a,b,c,e,f
CBT may improve
level of
functioning
(parent-rated) but
we are very
uncertain. Note:
lower scores
represent higher
level of
functioning.
Quality of life — SMD 0.39 higher
(0.02 higher to
0.77 higher)
— 223 (2) 4
Very low a,c,f
We are very
uncertain about
the effect of CBT
on quality of life.
Adverse events 319 per 1,000 338 per 1,000
(297L389)
RR 1.06
(0.93L 1.22)
275 (3) 44
LOW a,c
CBT appears to
result in little to
no difference in
adverse events.
Lack of remission 924 per 1,000 462 per 1,000
(342L619)
RR 0.50
(0.37L 0.67)
480 (7) 4
Very low a,b,e,g
CBT may reduce
lack of remission,
but we are very
uncertain.
(continued)
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TABLE 1 Continued
CBT vs. SSRI for OCD in Children and Adolescents
Outcomes
Anticipated Absolute Effects
(95% CI) Relative Effect
(95% CI)
No. of
Participants
(Trials)
Certainty of the
Evidence
(GRADE) CommentsRisk With SSRI Risk With CBT
Severity of OCD The mean severity
of OCD was 0.75
lower in CBT
(3.79 lower to
2.29 higher)
— 146 (3) 4
Very low a,c
CBT appears
comparable to
SSRI in reducing
severity of
obsessive-
compulsive
disorder, but we
are very
uncertain.
Serious adverse
events
0 per 1,000 0 per 1,000 (0L0) Not estimable 40 (1) - There was
insufficient data
to evaluate the
effect on serious
adverse events.
Level of
functioning
(patient-rated)
- MD 6.95 lower
(0.15 lower to
13.75 lower)
— 50 (1) 4
Very low a,c,f
We are uncertain
about the effect
of CBT
compared to
SSRI on level of
functioning
(patient-rated).
Note: lower
scores represent
higher level of
functioning.
Level of
functioning
(parent-rated)
- MD 1.70 lower
(9.85 lower to
6.45 higher)
— 50 (1) 4
Very low a,c,d
We are uncertain
about the effect
of CBT
compared to
SSRI on level of
functioning
(parent-rated).
Note: lower
scores represent
higher level of
functioning.
Quality of life Not estimable Not estimable Not estimable 0 - There were no
available data to
evaluate the effect
on quality of life.
Adverse events Not estimable Not estimable Not estimable 0 - There were no
available data to
evaluate the
effect on adverse
events.
(continued)
Journal of the American Academy of Child & Adolescent Psychiatry www.jaacap.org 73
Volume 59 / Number 1 / January 2020
CBT FOR PEDIATRIC OCD
TABLE 1 Continued
CBT vs. SSRI for OCD in Children and Adolescents
Outcomes
Anticipated Absolute Effects
(95% CI) Relative Effect
(95% CI)
No. of
Participants
(Trials)
Certainty of the
Evidence
(GRADE) CommentsRisk With SSRI Risk With CBT
Lack of remission 760 per 1,000 646 per 1,000
(502L828)
RR 0.85
(0.66L 1.09)
106 (2) 4
Very lowa,c,d,g
We are uncertain
about the effect
of CBT
compared to
SSRI on
remission.
Note: The risk with CBT (and the 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%
CI). The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group grades of evidence are as follows: High
certainty ¼We are very confident that the true effect lies close to that of the estimate of the effect; Moderate certainty ¼We are moderately confident
in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; Low
certainty ¼ Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect; Very low
certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. CBT ¼
cognitive-behavioral therapy; MD ¼ mean difference; OCD ¼ obsessive-compulsive disorder; RR ¼ risk ratio; SMD ¼ standardized mean difference;
SSRI ¼ selective serotonin reuptake inhibitors.
aAll trials were at an overall high risk of bias.
bSubstantial statistical heterogeneity was present and was not explained by planned or post hoc subgroup analyses.
cThe sample size was insufficient to calculate a precise effect estimate.
dThe CI around the effect estimate included both meaningful benefit and harm.
eThere was wide variation in effect estimates across trials.
fThe CI around the effect estimate included both meaningful benefit and no effect.
gRemission was assessed in nonstandardized and potentially invalid manners.
UHRE et al.analysis suggested that this may be a random finding due to
lack of power or multiple testing.
All included trials were assessed at high risk of bias,
and the certainty of the evidence was rated as low or very
low for all outcomes for both comparisons. Trials eval-
uating effects of psychotherapy are inherently more prone
to performance bias compared to trials evaluating effects
of medication,52-54 as it is not feasible to blind psycho-
therapists to the treatment they are providing. However,
issues remained that could have been avoided. Several
trials used unblinded outcome assessors or had unclear
allocation concealment. Intervention effects on subjec-
tively assessed outcomes (eg, CY-BOCS score) have been
shown to be exaggerated by 25% in trials with inadequate
or unclear blinding compared to trials with adequate
blinding, and by 31% in trials with inadequate or unclear
allocation concealment compared to trials with adequate
allocation concealment.52 Allocation concealment is al-
ways feasible, and the use of credible control in-
terventions (eg, placebo psychotherapy) can limit
performance bias.18 Only one of the included trials40 was
assessed at low risk of bias on all other domains than the
performance bias domain, highlighting a need for addi-
tional rigorous trials.74 www.jaacap.orgThis review updates and extends findings from pre-
vious reviews. To our knowledge, this is the first review to
assess the effects of CBT on adverse events, level of
functioning, and quality of life in children and adoles-
cents with OCD. In addition, we performed sensitivity
analyses to assess the potential impact of missing data,
and used TSA to control for risks of false-positive and
false-negative results. This allowed us to determine
whether a clinically meaningful and statistically signifi-
cant difference, or lack of a difference, between CBT and
a control intervention was likely to be a random finding
due to missing outcome data bias, lack of power, or
multiple testing.
Our review revealed an overall lack of data on
beneficial and harmful effects of CBT beyond OCD
symptom severity. All included trials assessed symptom
severity measured on the CY-BOCS as a primary
outcome. Most trials also included a measure of
remission, but methodological limitations, such as
dichotomizing a continuous outcome (CY-BOCS) and
using varying arbitrary definitions of remission instead
of assessing remission with a standardized diagnostic
interview, raises serious concerns about both the reli-
ability and validity of this outcome.55 Few trialsJournal of the American Academy of Child & Adolescent Psychiatry
Volume 59 / Number 1 / January 2020
CBT FOR PEDIATRIC OCDassessed adverse events, level of functioning, and quality
of life. Although symptom reduction is arguably an
important outcome, a comprehensive and more com-
plete evaluation of CBT efficacy should also include
assessment of potential harmful effects (ie, adverse
events), quality of life, and level of functioning.56
Psychotherapy is often assumed to be associated with
minimal harm, but adverse events are rarely systemat-
ically monitored in psychotherapy trials.57 Differences
in the frequency or severity of harmful effects could be
decisive factors for clinicians and patients when
choosing between CBT and SSRIs, especially consid-
ering our finding of comparable beneficial effects.
Moreover, symptom reduction may have little relevance
to patients if not accompanied by noticeable improve-
ments in daily life well-being and functioning.
A potential methodological issue with the assessment
of OCD symptom severity in all included trials is that 4
of the 10 items that comprise the CY-BOCS total score
specifically address the patient’s ability to resist and
control obsessions and compulsions, which is a major
focus of exposure and response prevention in CBT.
Although inability to resist and control obsessions and
compulsions are core features of OCD symptomatology,
the heavy emphasis on items addressing these features
might inflate estimates of the effect of CBT when CBT is
compared with interventions that do not include expo-
sure and response prevention (eg, psychoeducation and
relaxation training or SSRI interventions). This potential
issue may be circumvented by testing whether group
differences persist when scores on these items are
excluded from the total CY-BOCS score, or by including
additional measures of benefits in future trials and
reviews.
In conclusion, CBT may be more effective than no
intervention and comparable to SSRI for pediatric OCD,
but high risk of bias in included trials and low certainty of
the evidence prevent firm conclusions regarding the effi-
cacy of CBT. In addition, we had insufficient data to
adequately explore potential reasons behind statistical
heterogeneity in the meta-analyses. For all outcomes, we
were unable to perform planned subgroup analyses based
on overall risk of bias, participant age, OCD severity, and
comorbidity status.
Based on the data reviewed, we have four recommen-
dations for future trials in this field. First, future trials
should be designed in accordance with the standardJournal of the American Academy of Child & Adolescent Psychiatry
Volume 59 / Number 1 / January 2020protocol items: recommendations for interventional trials
(SPIRIT) guidelines58 and reported according to the
consolidated standards for reporting of trials (CONSORT)
guidelines.59 Second, we recommend that future trials
define remission from OCD as not fulfilling the diagnostic
criteria according to ICD or DSM and determine remission
with a blinded standardized diagnostic interview. Third, we
encourage trialists to include additional outcomes pertaining
to treatment effects beyond symptom reduction, such as
measures of quality of life and level of functioning. Fourth,
we urge authors of future trials to systematically monitor
and report adverse events for all comparison groups.Accepted September 27, 2019.
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